These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12394605)

  • 1. Sirolimus (Rapamune) in renal transplantation.
    Johnson RW
    Curr Opin Nephrol Hypertens; 2002 Nov; 11(6):603-7. PubMed ID: 12394605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety.
    Velosa JA; Larson TS; Gloor JM; Stegall MD
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S3-S10. PubMed ID: 11583938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
    Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
    Pescovitz MD; Govani M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit-risk assessment of sirolimus in renal transplantation.
    Kuypers DR
    Drug Saf; 2005; 28(2):153-81. PubMed ID: 15691225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation.
    MacDonald AS
    Transplant Proc; 2003 May; 35(3 Suppl):201S-208S. PubMed ID: 12742497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK; Chueh SC; Hu RH; Lee PH
    J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing calcineurin inhibitor drugs in renal transplantation.
    Flechner SM
    Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus: a new option in transplantation.
    Mota A
    Expert Opin Pharmacother; 2005 Mar; 6(3):479-87. PubMed ID: 15794738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM; Grinyó JM
    Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA; Heizer KE
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients.
    Hricik DE
    Transplant Proc; 2003 May; 35(3 Suppl):73S-78S. PubMed ID: 12742471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
    Drugs R D; 1999 Jan; 1(1):100-7. PubMed ID: 10566001
    [No Abstract]   [Full Text] [Related]  

  • 20. Can Rapamune replace cyclosporine? No significant difference in rejection rate after six months; long-term studies needed.
    Nephrol News Issues; 2000 Aug; 14(9):S9-10. PubMed ID: 11933435
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.